Pharmacological and immunological targeting of tumor mesenchymalization

Pharmacological and Immunological Properties of Wasp Venom

Animal toxin envenomations have medical as well as ecological significance. Toxin-producing animals are categorized under either venomous group or poisonous group. Venomous animals are capable of producing and delivering the toxin during a biting or stinging act whereas poisonous animals are those whose tissues, either in whole or in part, are toxic. [1] About 75% of the world’s animal species ...

Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis

Members of the transforming growth factor beta (TGF-beta) family have been genetically linked to vascular formation during embryogenesis. However, contradictory studies about the role of TGF-beta and other family members with reported vascular functions, such as bone morphogenetic protein (BMP) 9, in physiological and pathological angiogenesis make the need for mechanistic studies apparent. We ...

Computational Models of pharmacological and immunological treatment in Alzheimer’s disease

The immunological identity of tumor

By means of well-characterized autoimmunity models, we comparatively probed the "selfness" of malignant cells and their normal counterparts. We found that tumors activate self-tolerance mechanisms much more efficiently than normal tissues, reflecting a status of immunoprivileged "self." Our findings indicate that potent autoimmune responses can eradicate established malignancies, yet the collat...

Immunological targeting of cytomegalovirus for glioblastoma therapy

Human cytomegalovirus (CMV) is purportedly present in glioblastoma (GBM) while absent from the normal brain, making CMV antigens potentially ideal immunological anti-GBM targets. We recently demonstrated that patient-derived CMV pp65-specific T cells are capable of recognizing and killing autologous GBM tumor cells. This data supports CMV antigen-directed immunotherapies against GBM.